Sandra C. Raymond, President & CEO of the Lupus Foundation of America, issued the following statement in response to Eli Lilly and Company’s announcement of the results of two Phase III clinical trials of tabalumab.
News & Stories
The Lupus Foundation of America congratulates and welcomes the first 11 new research groups that have been awarded grants as part of the Accelerating Medicines Partnership in Lupus and Rheumatoid Arthritis (AMP Lupus and RA) Network.
Increasing funding for lupus research is a top priority for the Lupus Foundation of America. We urge Congress to robustly fund the National Institutes of Health (NIH), the largest source of biomedical research (and lupus) funding in the country.
Leading Orgs Take to the Hill to Discuss Need to Accelerate New Medicines for Lupus & Other Diseases
Lupus Foundation of America and Rheumatology Research Foundation hold congressional briefing
Jennifer Mall, M.P.H. discusses her research project as part of her Gina Finzi Fellowship experience during the summer of 2014.
Study funded by the Foundation's National Lupus Research Program secures NIH planning grant to develop a multi-center trial of mesenchymal stem cells.
Flare rates among participants receiving a low dose of the b-cell blocker did not meet primary endpoint but were lower for individuals receiving a higher dose.
Treat-to-Target is a treatment approach that has been used successfully in other diseases, including rheumatoid arthritis and diabetes. An international group of lupus experts has developed a set of recommendations for using this principle in lupus.
An international group of lupus experts has developed a set of recommendations to implement the treat-to-target strategy for managing lupus.
Lupus Foundation of America announces its 2014 National Lupus Research Program Summer Fellowships and Career Development Awards
Epigenetics is a field of science that examines factors which influence whether genes are turned on or off when cells are replicated, which can influence whether a person might develop a specific disease, such as lupus.
Bruce Richardson, M.D., Ph.D., of the University of Michigan, was honored for his research findings that have made significant contributions to the field and have a high likelihood of generating further insights in understanding the disease.
Additional data from the CDC National Lupus Patient Registry project demonstrates that lupus is a widespread disease with a significant impact.
Dr. Richardson’s work has provided a strong foundation from which further advances in the understanding and treatment of lupus can be made.
The Lupus Foundation of America announced today that the Foundation is seeking grant applications to provide critical funding that will, for the first time, address an unmet need in pediatric lupus nephritis.
A new study published in Arthritis Care & Research offers a first time, in-depth look at educational and employment outcomes in adults with childhood-onset lupus and provides new insights into properly navigating the path from adolescence to adulthood.
Lupus Science & Medicine™ is launched to provide the latest lupus research and stimulate collaborative efforts to improving the lives of all people affected by lupus.
The stories of four people whose lives have been forever changed by lupus and the Foundation's efforts to improve the quality of life for everyone affected by lupus.
LFA-REAL will address major challenges in lupus treatment and disease management, and has the potential to greatly improve medical care and quality of life for people living with lupus.
Sandra C. Raymond, President and CEO of Lupus Foundation of America, was featured on BioCentury This Week to speak about lupus and the Accelerating Medicines Partnership (AMP). Watch now!
A bird’s eye view of lupus research from the Lupus Foundation of America’s Education and Research Department
Congress passed the Consolidated Appropriations Act of 2014. While this funding brings some good news in the fight against lupus, the Act only restores some of the money to the NIH that was previously cut through the automatic spending reductions (sequestration).
Study examines the effects of the antimalarial drug, hydroxycloroquine, on antiphospholipid antibodies that are responsible for pregnancy complications in women with lupus and antiphospholipid syndrome.
Information about burden of disease and quality of life will help guide policy, program and investment decisions to solve the cruel mystery of lupus.
This valuable tool will help doctors prevent atherosclerosis, a life-threatening complication of lupus.
The Lupus Foundation of America will partner with the Foundation for the National Institutes of Health (FNIH) to support a new $230 million, five-year initiative that will accelerate the ability to develop new medicines for lupus and other diverse and complex diseases.
New LIFELINE Grant Will Help Sustain Lupus Research That’s at the Brink of Breakthrough.
Lupus Foundation of America supported study finds combination therapy that includes hydroxychloroquine may be beneficial to pregnant patients with lupus and/or antiphospholipid syndrome.
The Lupus Foundation of America applauds Congress for enacting the Consolidated Appropriations Act of 2014, H.R. 3547 which provides funding for vital lupus research and education programs.
As 2013 comes to an end, Sandra C. Raymond, President and CEO, reflects on the advances Lupus Foundation of America has made over the years, and speaks about the key priorities for the future.
Our research, education and advocacy programs in 2013 contributed advances that are helping to solve the cruel mystery of lupus.
Lupus Insight Prize to be awarded to Outstanding Scientist
Lupus Foundation of America medical director Dr. Joan Merrill discusses a recently completed a study that may help to improve the design for future lupus clinical trials and secure approval of new safe and more tolerable treatments for lupus.
Dr. Miriam Kaufman discusses a smartphone app that helps adolescents make the transition from pediatric to adult lupus care.
Dr. Hermine Brunner of the Cincinnati Children's Hospital discusses her research on health-related quality of life in children and adolescents with lupus.
Dr. Gary Gilkeson of the Medical University of South Carolina discusses his Lupus Foundation of America funded study on the potential use of human mesenchymal stem cells as a therapy for lupus.
Dr. Kenneth Kalunian discusses the Lupus Foundation of America Collective Data Analysis Initiative (LFA CDAI) which is providing insight into the impact various background medications may have on lupus clinical trial outcomes.
Data obtained from a large insurance claims database highlights the need for specific education and counseling to pregnant women with lupus as well as close collaboration between the rheumatologist and the obstetrician throughout the pregnancy
In her Expert Column, Dr. Joan T. Merrill, Medical Director, explains why antimalarial medicines are now used to treat lupus.
R. Paola Daly, Outcomes & Health Senior Manager, Lupus Foundation of America, shares her experience from the annual American College of Rheumatology meeting in San Diego and great tools she learned about on living well with lupus.
A new study that analyzed lupus treatment data from past global clinical trials suggests that when testing new drugs in combination with other background therapies, clinical trials should be designed to account for the effects that initial disease activity and background drug treatment have been shown to have on planned endpoints, like response and flare rates.
International knowledge healthcare provider BMJ and the Lupus Foundation of America have announced that they have joined forces to publish the first open access journal dedicated to lupus. Lupus Science & Medicine™ will offer timely global access to the latest scientific advances in lupus.
The U.S. Department of Defense (DOD) Medical Research Program announces two new lupus research grant awards, bringing the total DoD funds to date for support of lupus research to $14 million.
Learn what makes lupus so different from many other diseases and why lupus is a cruel mystery.
More than 250 lupus activists from 31 states joined the fight for more lupus research funding.
Senate Appropriations Committee approves a draft of the fiscal year (FY) 2014 Labor-Health and Human Services-Education appropriations bill.
Awards Will Support Efforts of Tomorrow’s Lupus Thought Leaders to Solve the Cruel Mystery of this Unpredictable and Devastating Disease
Lupus organizations have come together to launch a first-of-a-kind initiative to encourage scientific advances in lupus research with the Lupus Insight Prize.
Mark J. Shlomchik, M.D., Ph.D., the new incoming Chair of Immunology at the University of Pittsburgh, has been selected as the first recipient of the Lupus Insight Prize.
May is Lupus Awareness Month; Nationwide Efforts Underway to Solve the ‘Cruel Mystery’.
Congress funds vital lupus research and education programs by passing The Consolidated and Further Continuing Appropriations Act (H.R. 933).
Award is Created to Support Clinician-Scientists Transition From Training to Independent Careers in Lupus Research.
Achievements Highlight the Lupus Foundation of America’s Leadership Role in the Fight to End Lupus.
Studies Focus on Advancing Research and Improving Quality of Life for People With Lupus.
Dr. Ellen M. Ginzler Honored With Hess Award; Dr. Diane Leigh Kamen Receives Stevens Prize for Contributions to Lupus Research.
New Survey Shows Americans Know Little or Nothing About Disease That Affects1.5 Million.
Our national lupus research program aggressively seeks to advance the science and medicine of lupus and to improve the quality of life for all people affected by lupus.
Grants Given to Researchers Conducting Studies that Advance Science and Medicine of Lupus.
2012 Gina M. Finzi Memorial Student Fellowship Program Grantees Awarded
New guidelines help physicians screen, treat and manage adult lupus nephritis.
The Lupus Foundation of America is excited to see increased media attention surrounding lupus biomarkers, which are useful for diagnosing a disease.
Human Genome Sciences and GlaxoSmithKline released results of a survey highlighting a communication gap between people with lupus and the people who care for them.
Today, the Lupus Foundation of America (LFA) announced new research grants awarded to fund critical areas of research where gaps exist in the understanding and knowledge of lupus including: pediatric lupus, cutaneous (skin) lupus, mid-to-late stage translational research, adult stem cells, and neuropsychiatric lupus, which affects the brain and nervous system. The LFA’s National Research Program: Bringing Down the Barriers, is committed to accelerating the pace of medical discovery in lupus and directing support toward promising areas of study where other public and private organizations have not focused their efforts.
A pilot study shows early signs that a protein in the blood called C4d could serve as an indicator of lupus nephritis activity in people with lupus.
A new test has been launched to help physicians make a faster and more accurate diagnosis of lupus.
A report on a study funded by the Lupus Foundation of America found that males required a higher number of lupus susceptible genes to develop the disease.
Lupus Foundation of America Applauds Congress for Funding Vital Lupus Research/Education Initiatives
The Lupus Foundation of America applauds Congress for including vital lupus funding in the Fiscal Year 2012 Omnibus Appropriations Bill.
The New England Journal of Medicine published results from a long-term study for the treatment of lupus nephritis.
Dr. Deborah McCurdy and Dr. Ornella Rullo found that high levels of a protein called osteopontin may be a predictor of future lupus disease activity and organ damage.
Dr. Eyal Muscal of the Baylor School of Medicine reports on the results of a study that used advanced brain imaging to evaluate changes in the brains of adolescents with lupus.
LFA Funded Studies Focused on Advancing Research and Improving Quality of Life for People with Lupus
Investigators Present Research Findings at 2011 American College of Rheumatology Scientific Meeting.
Dr. Meenakshi Jolly, of Rush University Medical Center in Chicago, discusses the results of a study to validate an instrument to measure disease activity and quality of life.
The Lupus Foundation of America presented Graciela S. Alarcón, M.D., M.P.H, with the prestigious 2011 Evelyn V. Hess, M.D., M.A.C.P., M.A.C.R., Research Award.
Dr. S. Sam Lim presents data showing black women have a significantly higher incidence of systemic lupus erythematosus than most reports in the scientific literature.
Lupus Foundation of America Funded Research First to Use Pooled Data from Previous Treatment Trials.
The Rhuematologist features "The Lupus Initiative," a national health care provider education initiative to improve lupus diagnosis, treatment, and management among minorities.
The Lupus Foundation of America is pleased to announce the 2011 Gina M. Finzi Memorial Student Fellowship Program grantees.
LFA congratulates Bruce A. Beutle, Jules A. Hoffmann, and Ralph M. Steinman for receiving the 2011 Nobel Prize in Medicine.
The Lupus Foundation of America (LFA) Congratulates Trine Jorgensen, Ph.D., Cleveland Clinic Foundation and I-Cheng Ho, M.D., Ph.D., Brigham and Women’s Hospital
The Peer Reviewed Medical Research Program 2011 vision is to improve the health and well-being of all military service members, veterans, and beneficiaries.
LFA to honor Roch Doliveux, Chief Executive Officer, UCB; U.S. Senator Thad Cochran (MS); and Francis S. Collins, M.D., Ph.D., Director, National Institutes of Health.
The U.S. Food and Drug Administration (FDA) approved the drug, BENLYSTA®, for the treatment of lupus, an autoimmune disease.
Advocates from across the country will band together for lupus and urge Members of Congress to support increased federal funding for lupus research, awareness, and education.
The Lupus Foundation of America seeks grant applications from researchers to address the gaps in medical research that exist in key areas of lupus research.
Dr. William Stohl of the University of Southern California discusses the relationships among various parts of the immune system and their role in triggering lupus.
Dr. Joseph McCune of the University of Michigan discusses the role interferon and endothelial cells, which line blood vessels, as possible causes of increased risk of heart attacks and strokes associated with lupus.
Dr. Joseph McCune of the University of Michigan discusses preliminary data from the Michigan Lupus Registry and how this epidemiology study will help advance lupus research and treatment.
Dr. Amy Kao of the Allegheny-Singer Research Institute in Pittsburgh, discusses her research to evaluate the use of CD4 molecules on T-cells as a possible marker for diagnosing lupus nephritis and the potential benefits of a marker for this serious complication of lupus.
Dr. Jill Buyon of the New York University School of Medicine, a leading authority on congenital heart block in neonatal lupus, discusses this rare complication and the next steps in the study of neonatal lupus.
Dr. Kathleen O'Neil discusses a multi-center longitudinal observational study of girls with prepubertal onset lupus as they approach and pass through puberty, measuring hormone levels, autoantibodies and markers of lupus activity.
Dr. David Pisetsky of the Duke University Medical Center, discusses where lupus research may be headed in the coming years.
Dr. Gregg Silverman of the University of California, San Diego, discusses how the field of lupus genetics has evolved and where the field is headed in the next several years.
Dr. Gregg Silverman discusses B-cells and how they contribute to the development of lupus and offers insight on the future direction of lupus research.
Dr. David Pisetsky of Duke University Medical Center discusses the role of apoptosis (programmed cell death) and microparticles in triggering lupus.
Dr. David Pisetsky of Duke University Medical Center discusses immune response to DNA and its role in stimulating lupus.
Human Genome Sciences and GlaxoSmithKline announced publication of the BLISS-52 study of BENLYSTA®.
LFA-FLARE Definition Will Make Significant Contribution to Lupus Clinical Research
LFA-Funded Research Improves the Outlook for Childhood Lupus
Dr. Emily Von Scheven, Director of Pediatric Rheumatology at the University of California San Francisco Medical Center, discusses the issues surrounding bone health in children with lupus and other health issues associated with treatment of lupus.
Dr. Isenberg discusses several of the new agents under evaluation for lupus and looks to ways lupus treatment will change with evolving technology and new scientific findings.
Join us for our third annual Southwest Florida Walk to end Lupus now in Naples. Lets rally together to create awareness of lupus while raising funds to fight this terrible disease.
Don't miss this opportunity to learn from some of the world's leading lupus experts from the comfort and privacy of your home!
Learn how to reduce and cope with stress.
What you need to know to help with issues surrounding disability.
View upcoming support groups, educational programs, fundraising events, and more.
The walk is a one mile or 5k loop around a section of the UAH campus, beginning at the University Fitness Center. There is an indoor one mile loop available, as well. Registration begins at 3PM, and the walk kicks off at 5PM. Register today!
An educational symposium brought to you by the Lupus Foundation of America, Inc.
Feel empowered to advocate for yourself on a social and political level to overcome healthcare barriers.
The Mid-South Chapter is presenting its first "Living with Lupus" seminar in Huntsville, AL on Saturday, March 15, 2014. Dr. Winn Chatham will be presenting the topic, "Current & Promising New Approaches to Treating Lupus".
Educational symposium to be presented by LFA, PNW and Sisters Against Lupus (SAL)